Navigation Links
Multidisciplinary treatment of glioblastoma multiforme can extend patient's life
Date:8/12/2010

Glioblastoma multiforme is the most common form of brain cancer; being an extremely serious type of the disease as currently, on diagnosis, the chances of survival of the patient is less than a year. In fact, its cause is not known nor the manner to prevent it. What is more, progress of patients suffering from this condition has hardly changed in 40 years, unlike other cancers such as, for example, infant leukaemia, for which the possibilities of recovery have risen dramatically.

The Hospital Universitario Donostia (at the city of Donostia-San Sebastin in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicols Samprn, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.

As Dr Samprn explained, each year there are between three and six cases of glioblastoma multiforme for every 100,000 inhabitants and, thereby, between 30 and 40 new cases correspond to the Hospital Donostia annually. It is not, therefore, an infrequent illness. The new protocol incorporated into the hospital analysed in this thesis puts forward a more multidisciplinary approach to the treatment of patients suffering from this type of cancer. The key figure at the hospital is the Neuro-oncological hospitalisation committee or team, on which neurosurgeons, neurologists, cancer experts, anatomical pathologists, radiologists and others serve; all specialists involved in the care of these patients. The idea is, thus, to provide a more personalised treatment and monitoring.

17 months

According to the thesis, this new multidisciplinary approach gives better survival rates; the usual average survival rate for a patient with glioblastoma multiforme having been 12 months, after the incorporation of this treatment it has risen to 17 months and a half.

The thesis also highlights a finding as regards determining factors for prognosis. As Dr. Samprn pointed out, the general health situation of the patient at the moment of the diagnosis is the most efficacious indicative factor when predicting the most favourable prognosis, whereas molecular studies have not provided conclusive results with respect to this prognosis.


'/>"/>

Contact: Amaia Portugal
a.portugal@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related medicine news :

1. CIHR team grant to fund multidisciplinary breast cancer survivorship studies
2. Stem Cell Treatment May Offer Hope Against Fatal Skin Disorder
3. NIH award will enable design of brain tumor treatment that captures migrating cancer cells
4. New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
5. New anti-viral drug shows promise for dramatic improvement in hepatitis C treatment
6. Surgery better than radiation, hormone treatments for some prostate cancer, study shows
7. Drug control efforts in Mexico reduce methamphetamine treatment admissions in Mexico and US
8. MicroRNA molecule increases number of blood stem cells, may help improve cancer treatment
9. Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment
10. Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
11. New studies question vascular multiple sclerosis hypothesis and treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... MadgeTech ... are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With ... provide reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
(Date:5/26/2016)... ... 26, 2016 , ... In an effort to provide hair restoration information to the widest possible ... those who do not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair ... Live . , Dr. Mohebi says, “The positive response to the Snapchat videos we ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: